Paper Details

  1. Home
  2. Paper Details

Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study.

Author: CuzinBeatrice, GelbardMartin K, JonesNigel A, KaufmanGregory J, LevineLaurence A, LiuGenzhou, MarkStephen, RalphDavid J, TursiJames P

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Collagenase clostridium histolyticum (CCH) was found to be an effective treatment for Peyronie's disease (PD). In a phase 3 study, CCH significantly improved penile curvature deformity and PD symptom bother scores. CCH was generally well tolerated, with adverse events being mostly mild or moderate in severity and local to the penis.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: Collagenase clostridium histolyticum (CCH; Xiaflex, Auxilium Pharmaceuticals, Inc., Chesterbrook, PA, USA) is a Food and Drug Administration-approved, intralesional treatment for Peyronie's disease (PD). AIM: The aim of this study was to assess the safety and effectiveness of CCH in t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/25388099

データ提供：米国国立医学図書館（NLM）

Collagenase Clostridium Histolyticum: A New Hope for Peyronie's Disease

[Peyronie's disease] can be a challenging condition, impacting both physical health and emotional well-being. This study focuses on [collagenase clostridium histolyticum (CCH)], a [Food and Drug Administration (FDA)]-approved treatment for [Peyronie's disease]. Researchers conducted a [phase 3, open-label study] to assess the safety and effectiveness of CCH. The results suggest that CCH can be a valuable tool in managing Peyronie's disease.

CCH: A Promising Treatment for Peyronie's Disease

CCH, like a camel that can navigate challenging terrain, can effectively treat [Peyronie's disease]. The study found significant improvements in penile curvature deformity and symptom bother scores in patients treated with CCH. This offers a ray of hope for those struggling with this debilitating condition.

CCH: A Safe and Effective Treatment Option

This research, like a reliable guide in the desert, offers a safe and effective treatment option for [Peyronie's disease]. The study found that CCH was generally well tolerated, with most adverse events being mild and local to the injection site. This provides reassurance to patients seeking treatment for this condition.

Dr.Camel's Conclusion

This study is a beacon of hope in the desert of [Peyronie's disease] treatment. The findings highlight the safety and efficacy of CCH, providing a valuable treatment option for patients seeking to improve their quality of life.

Date :
  1. Date Completed 2015-07-13
  2. Date Revised 2022-03-10
Further Info :

Pubmed ID

25388099

DOI: Digital Object Identifier

S1743-6095(15)30881-X

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.